News Related to Entresto (Sacubitril/Valsartan)

Related coverage linked through entity extraction aliases.

Novartis reported 2025 sales of $54.5 billion as Amarin revenue fell 6.5%

Apr 22, 2026

Novartis reported 2025 sales of $54.5 billion, up 8%, while earnings per share rose 15% to $8.98. Amarin reported fiscal 2025 revenue of $213.6 million, down 6.5%, and narrowed its net loss per share to $0.09 from $0.20.

Pharma Faces $200-300 Billion Patent Cliff Through 2032 as Blockbusters Lose Exclusivity

Feb 16, 2026

The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.